Previous trials have shown that the active sub-stance eribulin can trigger fewer side effects compared to other chemotherapy drugs, which is why the treatment with eribulin was investigated in this trial.

In this trial we wanted to find out how effective and well tolerated eribulin is in older patients. In this trial, by contrast, eribulin was administered as the first chemotherapy in advanced breast cancer (first-line chemotherapy). Eribulin is already approved in Switzerland for the treatment of advanced breast cancer.